Director, HEOR Strategy

At Lilly, the work is demanding because patients are waiting. We unite caring with discovery to help make life better for people around the world, knowing that every decision, every detail, and every day matters. Headquartered in Indianapolis, Indiana, our over 50,000 employees around the globe take on complex challenges to discover and deliver life‑changing medicines, strengthen how health is understood and managed, and support the communities we serve.

This is hard, urgent, selfless work—but it’s work worth doing. If you’re driven by purpose and ready to bring your best to work that truly matters for patients, we invite you to join us.

At Lilly, the work is demanding because patients are waiting. We unite caring with discovery to help make life better for people around the world, knowing that every decision, every detail, and every day matters. Headquartered in Indianapolis, Indiana, our over 50,000 employees around the globe take on complex challenges to discover and deliver life‑changing medicines, strengthen how health is understood and managed, and support the communities we serve.

This is hard, urgent, selfless work—but it's work worth doing. If you're driven by purpose and ready to bring your best to work that truly matters for patients, we invite you to join us.

The demand for high-quality health economic and outcomes research (HEOR) and real-world evidence (RWE) to support drug development, health technology assessment/access decisions, product differentiation, and clinical decision making continues to grow. The purpose of the Lilly Health Economic and Outcome Research team is to accelerate equitable patient access and transform healthcare delivery through the execution and communication of bold, high impact science.

The HEOR Strategy Director will provide strategic insight/leadership into the health outcomes (HO) evidence needs (e.g., health economics, patient reported outcomes, real world evidence, access and reimbursement) for Lilly’s portfolio. As an HEOR scientist within the cardiometabolic health (CMH) portfolio, this individual sets the real‑world evidence, patient‑reported outcome, and economic value strategy across one or more assets.

• Drives sustained integration of HEOR from early clinical development through commercialization depending on focus of role.
• Develops and oversees HO research strategy for compounds in the Lilly portfolio in the CMH business unit.
• Serves as the senior HEOR strategic partner on lead/core teams throughout development and/or commercialization
• Formulates and drives Patient Focused Outcome (PFO), Real World Evidence, and/or economic value strategies for priority products and geographies.
• Establishes consistent yet agile HEOR standards across the CMH portfolio, enabling evidence generation to scale as the pipeline evolves.

• Develops bold high impact science for products across the lifecycle, to influence and support evidence needs for Lilly products in support of improving patient outcomes.
• Applies technical expertise appropriate for the role (e.g., scope or depth in statistical analysis, economic modeling, clinical trials, PFO development, observational/ epidemiologic research, and health technology or other value assessment) within a therapeutic area.
• Applies disease state knowledge and research methods to solve HO issues associated with registration, pricing, reimbursement, and access initiatives

• Provide guidance and mentorship to junior scientists and colleagues in HEOR methodologies and best practices.
• Communicates technical expertise with business acumen in a simple, succinct way.
• Leads HO…